HOPE in Diabetic Kidney Disease (HyperpOlarised PyruvatE in Diabetic Kidney Disease)
Key facts
- Where
- Aarhus N, DániaSee the site
- Phase
- 2. fázis
Where in Dánia
- Aarhus UniversitetAarhus N, DániaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aarhus Universitet
- Trial code
- EU 2023-508824-36-00
- Record updated
- 2025. február 12.
- Original description
We hypothesise that classification of diabetic kidney disease progression is possible with the application of quantitative hyperpolarised [1-13C]pyruvate MRI.Read full original descriptionShow less
QUANTITATIVE RENAL HYPERPOLARIZED [1-13C]PYRUVATE PERFUSION AND METABOLIC IMAGING IN DIABETIC KIDNEY DISEASE
We hypothesise that classification of diabetic kidney disease progression is possible with the application of quantitative hyperpolarised [1-13C]pyruvate MRI.
Inclusion: All participants: Aged 18 – 85 years and pre-menopausal women must be confirmed non-pregnant; Type 1 Diabetes Mellitus with diabetic kidney disease: eGFR > 15ml/min and eGFR=< 60 ml/min and urine albumin-creatinine ratio > 100 mg/g); Type 1 diabetes mellitus without diabetic kidney disease: eGFR > 60 ml/min and no albuminuria (urine albumin-creatinine ratio < 30 mg/g) and No signs of proliferative retinopathy or macular edema; Control Subjects must have eGFR>60.
Exclusion: Contraindications for MRI: Significant cardiac disease, Obstructive lung disease, pacemaker, neurostimulator, cholera implant, metal foreign bodies, claustrophobia, largest circumference including arms > 160 cm; Competing systemic diseases; Pyruvate Allergy; Stents or other devices implanted close to the kidneys that may cause imaging artifacts.